New blood-based diagnostic test for breast cancer demonstrates detection power of protein biomarkers irrespective of breast density

NEW YORK, Dec. 06, 2016 -- Provista Diagnostics, Inc., today announced that it will present exhibit posters at the San Antonio Breast Cancer Symposium (SABCS), taking place December 7-9, 2016 in San Antonio, Texas, related to its blood-based diagnostic test, Videssa^® Breast.

“The data we are presenting at SABCS demonstrate the important role that Videssa Breast can play in improving breast cancer detection and bringing greater clarity in clinical decision-making,” said Dr. Judith Wolf, Chief Medical Officer of Provista Diagnostics. “Despite advances in imaging technology, clinicians still face challenges in breast cancer detection, particularly in women with abnormal findings or dense breasts.”

Videssa Breast combines Serum Protein Biomarkers (SPBs) and Tumor-Associated Autoantibodies (TAAbs) to generate a unique protein signature for breast cancer detection, and the data to be presented result from Provista’s large, prospectively collected, blinded, randomized, multi-center clinical trials. The posters slated to be presented demonstrate how a blood-based test can help address key issues in breast cancer detection, including detection power in women with dense breasts, distinguishing benign findings from invasive disease and replicability of findings. The following posters will be presented:

Title: A Liquid Biopsy Test for Breast Cancer Detection Provides Consistent Diagnostic Results in Patients Over Six Months
Presenter: Dr. Judith Wolf
Date: Friday, Dec.9, 2016: 7:30-9:00 a.m. CT
Location: P4-01; Poster Session 4 - Hall 1.

Title: A Blood-Based Proteomic Videssa^® Breast Assay Performs Comparably in Women with Dense and Non-dense Breasts
Presenter: Dr. Judith Wolf
Date: Friday, Dec.9, 2016: 5:00-7:00 p.m. CT
Location: P5-03; Poster Session 5 - Hall 1.

“Clinicians need more tools to confidently rule out breast cancer or assess when further testing is truly warranted,” said Dr. Wolf. “These data demonstrate the ability of proteomic technologies to detect breast cancer early, improve decision-making and reduce the uncertainty and stress for women that too often come with breast cancer detection.”

For more information on Provista’s poster sessions at the San Antonio Breast Cancer Symposium Congress, please visit sabcs.org. For updates on the symposium, follow the hashtag #SABCS16 on Twitter, and follow Provista via @provistadx for company and data updates.

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

About the San Antonio Breast Cancer Symposium

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

Learn more about SABCS on the official website.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Jessica Schultz
JPA Health Communications
[email protected]
202-591-4005